Antony (France), 5 March 2014 – During its meeting held onMarch 5, 2014, the Board of Directors of Stallergenes announced the appointment of Christian CHAVY as Chief Executive Officer, to replace Roberto GRADNIK. This appointment will be effective on March 31, 2014.

The appointment of Christian CHAVY will enable the Group to pursue its strategy and to support Stallergenes in promising markets for immunotherapy, with a particular focus on the US market. Roberto GRADNIK will ensure a smooth transition and will provide consultancy services to the Board
of Directors during a four-month transitional period.

Patrick LANGLOIS, Chairman of the Board of Directors, commented:

"On behalf of the Board of Directors, I would like to warmly thank Roberto GRADNIK, who has successfully implemented a new organization adapted to the new operational challenges faced by the Group. Under his leadership, the Group made a major breakthrough, with the preparation and
submission of the application for commercial authorisation of Oralair® tablets in the US, which is currently reviewed by the FDA, and the definition of a long-term strategy, with a particularly strong focus on international markets. The appointment of Christian CHAVY represents a continuation of this
strategy. His recognised management skills, his international experience and considerable knowledge of the pharmaceuticals industry will enable Stallergenes to continue its expansion into promising markets for immunotherapy and in particular to ensure the success of Oralair® in the US market."

In 2010, Christian CHAVY joined ARES Life Science, an investment fund dedicated to healthcare. Previously, he served as President of Global Operations for Actelion Pharmaceuticals (USA, Europe, Japan and rest of the world). Prior to joining Actelion, he was Vice President at the reproductive medicine strategic unit of Serono in Geneva and Chairman of Serono's French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France. Christian CHAVY is a graduate of ESSEC and Institut de
Contrôle de Gestion de Paris (ICG).


Investor and analyst relations

Peter Buhler

Chief Financial Officer

Phone: +33 1 55 59 20 95

Email: [email protected]

Investor and press relations agency

FTI Consulting – Analyst and investor contact

Stephan Dubosq

Phone: +33 1 47 03 68 16

Email:[email protected]

Media Relations

Lise Lemonnier

Senior Communication & Public Affairs Director

Phone: + 33 1 55 59 20 96

Email: [email protected]

FTI Consulting – Press contact

Jeanne Bariller

Phone: +33 1 47 03 68 63

Email:[email protected]


Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.